Physician profile
Nitin Bhasin
NPI 1669790838
$6,882.82
in general payments reported to CMS, 2019-2025
28 companies · $838 in 2025
The $838 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $475 · 2021: $796 · 2022: $948 · 2023: $692 · 2024: $2,141 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,759 · Travel and Lodging: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,759.23 |
| Travel and Lodging | $911.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,394.52 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $958.09 | 2019-2024 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $636.53 | 2019-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $574.62 | 2019-2025 | Jynarque |
| Amgen INC. | $463.70 | 2019-2025 | Aranesp, Parsabiv, Krystexxa |
| Mallinckrodt Hospital Products INC. | $381.03 | 2020-2025 | Acthar |
| Calliditas Therapeutics US INC. | $335.07 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $242.38 | 2019-2025 | Velphoro, Velphoro, Crit-Line |
| Glaxosmithkline, LLC. | $228.26 | 2021-2024 | Benlysta |
| Alexion Pharmaceuticals, INC. | $225.10 | 2019-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $223.45 | 2021-2024 | Lupkynis |
| Vifor Pharma, INC. | $221.44 | 2019-2023 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $158.88 | 2020-2023 | Krystexxa |
| Novo Nordisk INC | $123.01 | 2024-2025 | Ozempic, Rybelsus |
| Mallinckrodt Enterprises LLC | $121.80 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $111.49 | 2022-2025 | |
| Ultragenyx Pharmaceutical INC. | $110.88 | 2019-2024 | Crysvita |
| Travere Therapeutics, INC. | $94.96 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $64.10 | 2019-2023 | Rayaldee |
| Cormedix INC. | $54.91 | 2024-2025 | Defencath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.39 | 2024 | Jardiance |
| Gilead Sciences, INC. | $32.11 | 2024 | |
| Boston Scientific Corporation | $25.94 | 2021 | |
| Genzyme Corporation | $22.28 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.63 | 2019 | |
| Csl Behring | $17.25 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Bhasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.